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Abstract 
 
The association between increased uric acid (UA) levels and cardiovascular disease 
(CVD) has been observed and studied for many decades. The value of UA as an in-
dependent factor within the metabolic risk profile for prediction of CVD in the normal 
population remains an issue of ongoing discussion. In turn, increasing evidence sug-
gests that among patients with established CVD such as heart failure UA is an inde-
pendent marker of disease state and prognosis. Increased UA levels may be an indi-
cator of up-regulated activity of xanthine oxidase, a powerful oxygen radical– gener-
ating system in human physiology. Increased reactive oxygen species (ROS) accu-
mulation contributes to endothelium dysfunction, metabolic and functional impair-
ment, inflammatory activation, and other features of cardiovascular pathophysiology. 
Accordingly, inhibition of xanthine oxidase activity has been shown to improve a 
range of surrogate markers in patients with CVD, but this effect seems to be tailored 
to hyperuricemic patients because disappointing results were reported in studies with 
normouricemic patients. In this review we summarize current evidence on hyperu-
ricemia in CVD. The value of UA as a biomarker and as a therapeutic target for tai-
lored metabolic treatment in CVD is discussed.  
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It has been observed for more than 50 years that hyperuricemia is associated with 
cardiovascular disease (CVD). Increased uric acid (UA) levels are a common obser-
vation in patients with CVD and a wealth of data have been accumulated that ad-
dress UA as a cardiovascular risk factor. In fact, hyperuricemia is closely associated 
with hypertension, insulin resistance,1 and other metabolic derangements (for review 
see Feig et al2). Accordingly, hyperuricemia has been added to the insulin resistance 
syndrome,3 a cluster of metabolic abnormalities that are addressed clinically as 
metabolic syndrome. The discussion continued, however, as to whether UA is truly 
an independent predictor of coronary heart disease (CHD) or merely an embedded 
component within this metabolic syndrome. Many analyses have addressed this is-
sue in prospective studies, registries, surveys, and cohort studies that cannot be dis-
cussed here in detail. A recent prospective study in 6,418 subjects plus a meta-
analysis of 16 studies with a total of 9,458 patients with incident CHD and 155,084 
controls found no convincing independent impact of UA. The odds ratio for patients in 
the top third compared with the bottom third of UA levels was 1.13 (95% confidence 
interval [CI], 1.07-1.20) in the total study population (males, 1.12; 95% CI, 1.05-1.19; 
females, 1.22; 95% CI, 1.05-1.40) to develop CHD in the subsequent decade. This 
ratio was reduced to a nonsignificant result of 1.02 (95% CI, 0.91-1.14) in the eight 
studies in which more complete adjustment for relevant confounders was possible.4 
The conclusion from these results was that serum UA levels are unlikely to be a ma-
jor determinant of CHD and may not contribute importantly to the prediction of CHD 
in the general population. However, the discussion is ongoing because contrasting 
data also recently have been reported that observed UA as indeed a significant 
prognostic marker of cardiovascular events including myocardial infarction, heart fail-
ure, stroke,5 and cardiovascular death.6 In specific patient populations UA neverthe-
less may carry predictive information such as in stroke survivors, in whom a three-
fold increased risk for cardiac death was observed regardless of the use of diuretics 
and after adjustment for age, sex, and several metabolic confounders. 7 In addition, 
in patients with increased risk of or with established CHD disease UA was observed 
to predict prognosis.8,9 In patients with heart failure there is substantial evidence that 
increased UA levels are highly predictive of increased morbidity and mortality both in 
acute and chronic diseased patients. This is discussed in the next section.  
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HYPERURICEMIA IN CONGESTIVE HEART FAILURE: DISEASE SEVERITY AND 
MORTALITY  
Hyperuricemia is a common observation in patients with congestive heart failure 
(CHF) and an association with disease severity according to New York Heart Asso-
ciation functional class10 or with symptomatic impairment in exercise capacity has 
been observed.11 Notably, in these CHF patients, hyperuricemia does not depend on 
the presence of a metabolic syndrome risk profile for ischemic heart disease. Pa-
tients with ischemic and nonischemic heart failure showed a similar distribution of UA 
levels according to New York Heart Association classes. UA levels also were ob-
served to carry powerful prognostic information in patients with CHF. Increased risk 
of all-cause death was observed in a dose-dependent relationship with hyperuricemia 
with as much as an 18-fold increased risk in those patients with UA levels greater 
than 800 µmol/L (Fig. 1).12 The prognostic significance of high UA levels was inde-
pendent of other established prognostic factors in CHF and added predictive power 
to established prognostic models such as the heart failure survival score.12 A recent 
large case-control analysis studied more than 25,000 patients (mean age, 77 y; me-
dian follow-up period, 2.1 y) who were discharged from the hospital with the recent 
diagnosis of heart failure.13 A history of gout or an acute gout episode were inde-
pendent risk factors for increased mortality or hospital re-admission for heart failure. 
In turn, the use of allopurinol improved outcome in these patients. Other studies also 
have shown similar results in patients with moderate heart failure (HF)14 and in those 
with acute HF.15,16 Accordingly, UA level has been included as independent factor in 
the Seattle Heart Failure Survival Score.17 Moreover, a recent study in nonischemic 
heart failure patients showed that increased serum uric acid level (>8.7 mg/dL) car-
ried even stronger prognostic information than N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) on cardiac events (composite of cardiac death and hospitalization 
for heart failure.18 For clinical use as a disease marker it would be desirable to estab-
lish one or several cut-off points for UA levels in CHF patients that provide clear 
guidance as to increasing risk. No such limits are currently available. Several aspects 
need to be discussed in this context. The range of normal physiologic values of UA is 
genderdependent and follows a Gaussian distribution with slightly higher values in 
men than in women. The cut-off points for hyperuricemia as currently applied in stud-
ies are based on (gender-independent) limits of serum solubility of UA in which pre-
cipitation of UA (ie, acute gout) becomes imminent. Although useful in gout patients, 
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these limits may not be applicable to reflect the association of UA with morbidity and 
mortality in HF patients. Several cut-off points for UA levels have been proposed for 
HF populations based on findings in individual study populations. They range from 
6.5 mg/dL or higher in patients with mild to moderate HF14 to 8.7 mg/dL18 and 9.5 
mg/dL12 in patients with more advanced CHF and from 7.0 mg/dL15 to 7.7 mg/dL in 
patients with acute HF.16 Further work is needed to establish and validate a more 
consistent grading system for hyperuricemia to improve clinical applicability of UA as 
a disease marker.  
 
 
HYPERURICEMIA: ACTIVE PLAYER OR MERE MARKER IN THE DISEASE 
PROCESS?  
It is a matter of ongoing debate whether UA itself has a functional role in the patho-
physiology of heart failure or whether it is a mere marker of disease progression 
without functional involvement. In general, the finding of UA to predict outcome in 
patients with CHF does not presume a causal contribution from UA, nor would this be 
a requirement to use UA as a prognostic marker. The former perception of UA as a 
metabolically inert final step of purine degradation has changed because recent evi-
dence suggests a significant role of this enzymatic pathway and of UA itself within 
metabolic and immunologic regulation. UA has been identified as a principal endoge-
nous danger signal to cell injury that activates cellular immune response.19 It is pro-
duced constitutively in cells of all tissues and increasingly is released when cells are 
injured to stimulate dendritic cell maturation and T-cell response. This is in line with 
previous observations that infusion of UA in a mouse model triggered increased pro-
duction of tumor necrosis factor-α on endotoxin stimulation.20 In addition, other direct 
effects of UA have been observed such as promotion of low-density lipoprotein (LDL) 
oxidation21 and in vitro smooth muscle cell proliferation.22 To what degree these find-
ings have a relevant impact in patients with CVD needs to be established. Much 
more evidence has emerged to suggest UA as a marker of an up-regulated activity of 
the enzyme xanthine oxidase (XO). This is discussed in more detail in the following 
section. XO has been established as a major source of reactive oxygen species 
(ROS) and hence as an originator of a wealth of detrimental effects in various acute 
and chronic disease conditions including CVD. The complexity of the role of UA is 
complicated further because UA is an abundant antioxidant that accounts for much of 
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the protective free radical scavenging capacity in human plasma.23 Infusion of UA 
has been observed to increase antioxidant capacity and to decrease oxidative stress 
in healthy subjects.24 Accordingly, a protective function of hyperuricemia has been 
suggested for heart failure patients.25 This discussion is inseparably linked with the 
examination of the mechanisms of increased UA levels in CHF patients. A depend-
ency of increased UA levels on impaired renal function is often pointed out and in-
creasing UA levels therefore are discussed by some (see comment above) to be 
merely a reflection of impaired renal function. Indeed, renal impairment is frequent in 
CHF and UA excretion depends on renal function and might be compromised further 
by diuretic treatment in these patients. Several lines of evidence suggest, however, 
that hyperuricemia in these patients results from increased purine degradation from 
tissue turnover and from diversion of metabolites that are triggered by several factors 
including tissue hypoxia, 26 catabolism,10 insulin resistance, 27 and cell death. In-
creased substrate supply and direct stimulation such as from inflammatory cytokines 
and oxygen radicals28 accounts for up-regulated activity of the XO catabolic pathway 
as the predominating mechanism of hyperuricemia in CHF (Fig. 2).29 On this basis, 
overproduction rather than undersecretion is the underlying principle of hyperurice-
mia in CHF. First, direct assessment of XO has shown increased enzymatic activity in 
CHF.30-32 Second, treatment studies aimed at inhibition of XO showed several clinical 
benefits whereas therapies that decreased UA directly by increased renal excretion 
or by UA degradation did not yield comparable effects. This is discussed in detail 
later. The widely adopted current position in this discussion is that UA levels may in-
deed be more of a marker than an active player within the pathophysiology of CHF 
because UA reflects up-regulated XO activity. However, assessing serum UA is, op-
posite of direct assessment of XO, a widely available, well-standardized, simple, and 
inexpensive laboratory measurement. Given the powerful prognostic implication ob-
tained from UA levels, it has many of the desired characteristics of an ideal biomarker 
for evaluation of CHF patients.  
 
XO AS A SOURCE OF FREE OXYGEN RADICAL PRODUCTION  
A substantial body of evidence has established the oxygen radical– generating ca-
pacity of the UA-producing enzyme XO as a pivotal pathophysiologic feature of CVD. 
In fact, in 1968 cytosolic XO was the first documented biological system shown to 
produce oxygenderived free radicals.33 XO produces free oxygen radicals in 
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stoichiometric quantities along with UA and is one of the major sources of oxygen 
radical production in human physiology. For each oxidative step of hypoxanthine and 
xanthine two electrons are transferred to XO and the fully reduced XO6e- yields the 
production of two H2O2 and two O2.34 ROS accumulation accounts for a number of 
detrimental effects in CVD such as endothelium dysfunction, 35 impaired myocardial 
contractility, inflammatory activation, metabolic imbalance, and others. Notably, the 
enzyme xanthine oxidoreductase exists in two interconvertible forms, that is, xanthine 
dehydrogenase (XDH; EC 1.17.1.4) and XO (EC 1.17.3.2). Although UA is the enzy-
matic product of both forms, the XDH form has NAD+ as the preferred redox partner 
whereas in the oxidase form the enzyme is using oxygen as an electron acceptor, 
thus producing reactive oxygen species, mainly superoxide anion and H2O2 (Fig. 3). 
XDH is the predominant form in well-oxygenized tissue36 but readily is converted to 
XO under various conditions. 37,38 In turn, hypoxia/ischemia favors XDH to XO con-
version, which is a common condition in CVD patients. Notably, circulating XO can 
bind to the endothelium surface where its induced ROS-producing capacity signifi-
cantly contributes to further endothelial injury.39 Accordingly, in coronary arteries from 
patients with coronary artery disease (CAD) an increase of XO protein and its activity, 
but not of xanthine dehydrogenase protein levels, recently has been observed.40,41 
Increased endothelium-bound XO activity has been shown in CHF patients.31 More-
over, a redox-sensitive activation of endothelial XO activity is suggested from the ob-
servation that NAD(P)H oxidase– derived ROS production further stimulates XO-
derived superoxide production in endothelial cells.42 Although UA is produced in all 
tissues throughout the body, the highest activity of XO (apart from the lactating 
mammary glands) has been observed in the capillary endothelial cells43 of the intes-
tine and the liver.36 Given this specific distribution and the toxic effects of ROS, a 
role as a defense mechanism has been suggested, such as to protect the inner sur-
face (ie, the barrier between intestinal lumen and the body tissues) from an infectious 
pathogen invasion.44 It is a common pathophysiologic mechanism in human biology 
that well-tuned adaptive mechanisms intended as response to short-term injury may 
turn into maladaptive processes and lead eventually to harmful effects when acti-
vated in the long term such as in chronic disease conditions. The protective antioxi-
dant capacity of UA then may act as a negative feedback principle leading to contin-
ued ROS accumulation with deleterious effects including increased cytokine produc-
tion, 45 cell apoptosis,46 and endothelial dysfunction,47 all of which occur in chronic 
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diseases. It has been shown that endothelium-bound XO activity and protein levels 
are increased substantially in patients with coronary disease, 40,41 carotid steno-
sis,48 or chronic heart failure,30,31 and are related inversely to endothelium-
dependent vasodilation. 40  
 
XO-DERIVED ROS: IMPACT IN CVD  
A substantial body of evidence has accumulated showing a pathophysiologic in-
volvement of increased XO activity in CVD. Increased ROS production, in particular 
superoxide anions, interacts readily with endothelium-derived NO to form peroxyni-
trite (ONOO-, in itself a highly active oxygen radical), starting a cascade of detrimen-
tal oxygen radical effects.49 ROS accumulation has been suggested as a major 
cause of endothelial dysfunction in both experimental and clinical studies with CAD42 
in CHF.50 Besides impaired myocardial and peripheral tissue perfusion, direct effects 
on myocardial and skeletal metabolic and functional capacity result from an increase 
in ROS accumulation in CVD. Consequently, the therapeutic approach of XO inhibi-
tion seems to be an intriguing concept to counteract a range of these processes. In-
deed, several studies have observed an improved endothelium-dependent vasodila-
tion after allopurinol or oxypurinol therapy in patients with CAD or CHF.50-52 An indi-
rect effect of allopurinol on regulation of vascular tone via interaction with asymmetric 
dimethylarginine has been observed.53 In addition, multiple other pathophysiologic 
features in CVD were shown to be improved after XO inhibition (Table 1). From those 
proof-of-concept studies, further evidence has emerged that indeed XO activity rather 
than UA may be viewed as the true therapeutic target. Direct UA decreases with dif-
ferent approaches but without inhibition of XO was observed in several studies as 
ineffective to prevent detrimental effects seen in hyperuricemic patients. In these 
studies renal reabsorption inhibitors benzbromarone54 and probenecid55 were used to 
increase UA excretion, or the enzyme urate oxidase was used to promote the further 
degradation of UA to allantoin.56 UA levels were reduced with these therapies by 
34%, 46%, and 64%, respectively, which compares and even exceeds the UA lower-
ing effect of allopurinol in these patients. All three approaches failed, however, to im-
prove endothelium function or other measures of clinical status.  
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XO INHIBITION: A NOVEL THERAPY OPTION IN CVD?  
Treatment effects on CVD as outlined earlier showed beneficial effects in both animal 
models and clinical studies on various clinical and biochemical variables such as 
myocardial perfusion and contractility, peripheral vascular resistance, afterload, and 
BNP levels (Table 1). Although therapeutic effects on those surrogate markers of 
CVD are promising, the proof of XO inhibition as a valuable novel therapeutic ap-
proach would depend on evidence of improved mortality or clinically meaningful 
measures of morbidity. A large retrospective cohort study including 4,785 patients 
with CHF investigated the effect of allopurinol therapy on all-cause mortality in CHF 
patients with hyperuricemia.57 It was observed that highdose (sufficient) XO inhibition 
therapy with allopurinol resulted in a survival benefit as compared with insufficient 
(low-dose) XO inhibition in the hyperuricemic CHF subjects (hazard ratio, 0.65; 95% 
CI, 0.42-0.99). A comparison with an allopurinol-free normo-uricemic control group 
was considered unsuitable for this study because mortality risk is a priori substantially 
increased in patients with increased UA levels (Fig. 1). One prospective study has 
been undertaken so far to test the impact of XO inhibition on mortality in CHF.58 In 
this study, the OPT-CHF trial (impact of oxypurinol in patients with symptomatic heart 
failure), oxypurinol, the active metabolite of allopurinol, was used because it was 
considered superior to allopurinol. Allopurinol itself is a pro-drug that is converted into 
oxypurinol by XO in a superoxide radical– generating enzymatic step.59 Despite the 
convincing pathophysiologic concept and intriguing data from preclinical and pilot 
clinical trials, the study failed to show a benefit on the composite primary end point of 
HF clinical status and mortality. This disappointing result likely may diminish the in-
terest in further studies in this field. However, some aspects of the study design need 
to be discussed. Importantly, effective treatment effects may be expected only in pa-
tients in whom up-regulated activity of XO is truly apparent. As outlined earlier, the 
presence of hyperuricemia would be required as an indicator of high XO activity in 
CHF patients. Accordingly, in previous proof-of-concept treatment trials, effects were 
particularly observed in hyperuricemic patients.50,51,60 By contrast, this treatment ap-
proach repeatedly failed in patients with normal UA levels (Fig. 4). The OPT-CHF trial 
enrolled patients without screening for UA levels. Notably, in this trial the anticipated 
results were indeed observed only when those patients with increased UA levels 
(≥9.5 mg/dL) were analyzed. This subgroup analysis, however, was lacking the 
power and prospective character of the overall study analysis. It might be concluded 
 10 
that XO inhibition as a novel metabolic treatment approach in CHF might be suitable 
only in patients in whom increased UA levels are an indicator of up-regulated XO ac-
tivity. Extending this approach to patients with normal UA levels might increase the 
number of nonresponders.61 XO inhibition by allopurinol may as well be of interest in 
patients with CAD and stable angina pectoris. In a recent randomized controlled 
study of 65 patients with CAD and stable angina pectoris allopurinol therapy (600 
mg/d) significantly delayed the onset of ST-segment depression in the ECG and in-
creased total exercise time and time to chest pain in a symptom-limited treadmill ex-
ercise test (Bruce protocol).62 Notably, time to ST depression and total exercise time 
were increased to a similar extent as has been observed for anti-anginal medications 
in clinical use, such as nitrates, calcium antagonists, ß-blockers, and ivabradine. The 
underlying mechanisms for the potential antiischemic properties of allopurinol remain 
to be examined further. Previous studies have suggested that allopurinol reduces 
myocardial oxygen consumption and improves myocardial efficacy.63,64 Furthermore, 
effects to restore endothelial function after allopurinol or oxypurinol may contribute to 
reduced ischemia during exercise in CAD patients.42,52 Notably, a dose-response re-
lationship has been observed between allopurinol and its effect on endothelial func-
tion.55 This raises the possibility that high- dose allopurinol treatment may be required 
to exert antiischemic effects in patients with coronary disease. However, more data 
from larger studies will be needed to confirm the anti-anginal effects of allopurinol 
and to compare the efficacy with other established anti-anginal therapies. Allopurinol, 
after all, is burdened with substantial side effects such as severe skin reactions and 
renal impairment. Whether oxypurinol or newer compounds with less side effects 
such as febuxostat, a noncomparative selective XO inhibitor,65 may be better options 
for this targeted XO inhibition in CVD awaits further investigation.  
 
SUMMARY  
Hyperuricemia is a common finding in patients with CVD. It often is associated with 
the metabolic cluster within the metabolic syndrome. The discussion on the impact of 
UA as an independent risk factor in the normal population is ongoing but recent data 
suggest that it is unlikely that UA will significantly enhance the prediction of CVD in 
the general population. Among patients with established cardiac diseases, however, 
increased UA levels have been shown to be a powerful and reliable marker of ad-
vanced symptomatic disease state and a particularly poor prognosis. Assessment of 
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serum UA is a simple and nonexpensive laboratory measurement that ensures wide 
clinical availability. It has many of the desired characteristics of an ideal biomarker 
and should be assessed more regularly in cardiovascular patients, particularly in pa-
tients with CHF. Current evidence suggests that UA is more of a disease marker than 
an active player within the cardiovascular pathophysiology because high UA levels 
reflect up-regulated XO activity. The XO-derived ROS accumulation leads to NO 
scavenging and endothelium dysfunction but also to a variety of other detrimental 
metabolic, functional, and immunologic effects. Novel data are emerging to suggest 
as well direct effects of UA on immune stimulation and metabolic interference. In turn, 
UA has strong anti-oxidative potential and further work is needed to untangle the 
complex and at times conflicting interactions of UA. Recent clinical studies on the 
therapeutic effect of XO inhibition have suggested that XO inhibition could have a 
role as a tailored treatment option in hyperuricemic patients with CHF but may be 
unsuitable for nonselective use. Whether it may be applicable in CAD patients with 
stable angina to increase exercise endurance needs to be confirmed in further stud-
ies. Novel compounds for XO inhibition with more specific effects and less side ef-
fects may be a promising option to further explore the potential of this metabolic 
treatment in patients with CVD.  
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Figures 
 
 
 
Figure 1. Graded relationship of serum UA and survival in CHF patients. UA ≥ 400 
µmol/L = 6.72 mg/dL as reference group (HR, 1). *P < .05 and ****P < .0001 vs refer-
ent. Adapted from Anker and Doehner et al.12  
 
 
 
Figure 2. Increased serum UA levels in CHF origin from a combination of overpro-
duction and from undersecretion. TNFα, tumor necrosis factor α. Adapted from 
Doehner et al.29  
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Figure 3. Xanthine oxidoreductase (XOR; EC 1.17.3.2) exists in two interconvertible 
forms that use either NAD+ (XDH) or oxygen (XO) as redox partner. TNFα, tumor 
necrosis factor α.  
 
 
 
 
Figure 4. Efficacy of treatment with XO inhibitors depends on UA levels at enroll-
ment. Positive effects were observed in studies with increased UA levels whereas no 
effect was seen if UA levels were normal. Adapted from Doehner et al.62 
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